Keystone Pharmaceuticals and Stone Burning Medicine have reached a partnership on the accompanying diagnosis of Pralsetinib China.
-
Last Update: 2020-07-19
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On May 30, 2020, ASCO online meetings released the latest clinical data on non-small cell lung cancer (NSCLC) in the ARROW study being conducted worldwide, including the population of patients who received an initial dose of 400 mg per day and whose efficacy can be assessedas of November 18, 2019, the total remission rate (ORR) of pralsetinib treatment was 73% (95% CI: 52-88%) for 26 patients who had previously been treated with systemic treatment, and for 80 patients who had previously received chemotherapy with platinum, pralinibOR was 61% (95% CI: 50-72%)In 354 patients who received an initial dose of 400 mg daily, pralsetinib was well tolerated, and most treatment-related adverse events were level1 and 2The results of this study are very encouraging and show that pralsetinib has very good therapeutic prospects in RET gene fusion-positive NSCLC.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
